Código del ensayo BP42675 |
Ensayo An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of Ro7122290, A Fibroblast Activation Protein-A (Fap) Targeted 4-1Bb Ligand (Cd137L), In Combination With Cibisatamab With Obinutuzumab Pre-Treatment, In Participants With Previously Treated, Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High Ceacam5 Expression |
Estado Abierto a inclusión |
Localización Tumoral Digestivo |
Tipo de tumor Colon-Recto |
Tipo de ensayo Ensayo de Fase I |
Tipo de tratamiento Inmunoterapia |
Situación clínica Metastásico |
Centro |